Welcome to our dedicated page for DURECT news (Ticker: DRRX), a resource for investors and traders seeking the latest updates and insights on DURECT stock.
The DURECT Corporation (DRRX) news feed on Stock Titan aggregates historical company announcements, clinical updates, financial disclosures and transaction-related communications for this former Nasdaq-listed biopharmaceutical issuer. DURECT has described itself as a late-stage biopharmaceutical company focused on epigenetic therapies that target dysregulated DNA methylation, with particular emphasis on serious and life-threatening conditions such as alcohol-associated hepatitis (AH) and other forms of acute organ injury.
News items for DRRX include detailed updates on the development of the company’s lead investigational drug candidate, larsucosterol. These releases cover milestones such as the Phase 2b AHFIRM trial results, publication of data in NEJM Evidence, presentations at major liver disease meetings, and plans for a registrational Phase 3 trial in severe AH. Company communications also highlight that larsucosterol has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration for the treatment of AH.
The feed also captures DURECT’s corporate and portfolio developments, including announcements about its FDA-approved non-opioid analgesic POSIMIR, based on the SABER platform technology, and the sale of the ALZET osmotic pump product line. In 2025, a significant portion of the news flow relates to the tender offer and merger under which a subsidiary of Bausch Health Americas, Inc. agreed to acquire all outstanding shares of DURECT, followed by completion of the merger and subsequent delisting and deregistration of DRRX.
Investors and researchers can use this page to review historical earnings releases, business updates, clinical trial communications and acquisition-related announcements that together document DURECT’s evolution from a publicly traded company to an indirect wholly owned subsidiary within a larger pharmaceutical group.
DURECT Corporation (Nasdaq: DRRX) announced Timothy M. Papp as its new Chief Financial Officer on July 5, 2022. Papp brings over 25 years of corporate finance experience, including 15 years in biopharma, most recently from RBC Capital Markets. His role will encompass financial reporting, strategy, and investor relations. DURECT's lead candidate, larsucosterol, is in development for alcohol-associated hepatitis and has received FDA Fast Track Designation. The company also focuses on therapies for chronic liver diseases and has an FDA-approved product, POSIMIR, licensed to Innocoll Pharmaceuticals.
DURECT Corporation (Nasdaq: DRRX) will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on May 24, 2022, starting at 7:00 am Eastern Time. Key executives, including Dr. James E. Brown and Dr. Norman Sussman, will engage in the session hosted by Ed Arce. A webcast of the event will be available on DURECT's website. Additionally, from May 23-25, management will hold virtual 1x1 meetings. DURECT specializes in developing therapies for organ injury and chronic liver diseases, with its lead candidate, larsucosterol, in clinical trials for alcohol-associated hepatitis.
DURECT Corporation (Nasdaq: DRRX) reported its Q1 2022 financial results with total revenues of $1.9 million and a net loss of $10.8 million. This reflects a decrease in revenue compared to $2.2 million in Q1 2021. The company is advancing in the AHFIRM trial for larsucosterol, with increased patient dosing and the opening of new clinical sites, now totaling 57 sites globally. DURECT has a partnership with Innocoll Pharmaceuticals for POSIMIR, expected to generate royalties and milestone payments. Cash and investments decreased to $64.4 million.
DURECT Corporation (Nasdaq: DRRX) will report its first quarter 2022 financial results after market close on May 4, 2022. The conference call will take place at 4:30 PM ET. DURECT is focused on developing innovative therapies for acute organ injury and chronic liver diseases. Its lead candidate, Larsucosterol (DUR-928), has received Fast Track Designation for alcohol-associated hepatitis (AH) and is also being explored for non-alcoholic steatohepatitis (NASH). Further information can be found at www.durect.com.
DURECT Corporation (Nasdaq: DRRX) announced that its President and CEO, Dr. James E. Brown, will participate in a panel titled "Small but Mighty: Innovative Strategies in Tackling Some of the Larger Rare Orphan Disease Markets" at the Cantor Virtual Rare Orphan Disease Summit on March 30, 2022, at 1:00 PM ET. The event will be hosted by Kristen Kluska of Cantor Fitzgerald. DURECT focuses on developing treatments for acute organ injury and chronic liver diseases, with its lead drug candidate, Larsucosterol (DUR-928), receiving Fast Track Designation from the FDA.
DURECT Corporation (Nasdaq: DRRX) will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, from 1:20 PM - 1:50 PM EDT. Dr. James E. Brown, Dr. WeiQi Lin, and Dr. Norman Sussman will discuss the company’s progress in clinical development, focusing on their lead candidate, Larsucosterol (DUR-928), which targets alcohol-associated hepatitis and has received FDA Fast Track Designation. Additionally, the company’s non-opioid analgesic POSIMIR is licensed to Innocoll Pharmaceuticals for development in the U.S.
DURECT Corporation (Nasdaq: DRRX) reported its Q4 and full year 2021 financial results, highlighting total revenues of $7.3 million for the quarter and a net loss of $7.0 million, compared to $2.2 million and $8.8 million, respectively, in Q4 2020. Annual revenues decreased to $14.0 million from $30.1 million, with a net loss of $36.3 million. Progress in the AHFIRM trial includes over 100 patients dosed, and a licensing agreement for POSIMIR was signed with Innocoll, expected to generate up to $136 million. Cash and investments rose to $70.0 million.
DURECT Corporation (Nasdaq: DRRX) announced the dosing of its first patient in the EU for the Phase 2b AHFIRM study of larsucosterol in patients with severe alcohol-associated hepatitis (AH). This milestone marks progress in evaluating larsucosterol's efficacy and safety. The trial aims to enroll 300 patients across multiple regions, comparing larsucosterol with placebo and standard care. The FDA has granted Fast Track Designation for larsucosterol, emphasizing its potential to address a serious health issue. The primary outcome is the 90-day survival rate.
DURECT Corporation (Nasdaq: DRRX) will report its fourth quarter and full year 2021 financial results on March 7, 2022, at 4:30 PM ET. The conference call will provide insights into the company’s financial performance and business developments, including updates on its lead drug candidate, Larsucosterol (DUR-928), which is in clinical trials for treating alcohol-associated hepatitis (AH) and non-alcoholic steatohepatitis (NASH). DURECT holds Fast Track Designation from the FDA for Larsucosterol, reflecting its potential in treating serious liver diseases.
DURECT Corporation (Nasdaq: DRRX) announced participation in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022. Key executives—Dr. James E. Brown, Michael H. Arenberg, and Dr. Norman Sussman—will present on-demand starting at 7:00 A.M. EST on January 10. The webcast will be accessible via the company's website. DURECT is advancing innovative therapies for liver diseases, with its lead candidate, Larsucosterol (DUR-928), in clinical trials for alcohol-associated hepatitis and non-alcoholic steatohepatitis, holding an FDA Fast Track Designation.
FAQ
What is the current stock price of DURECT (DRRX)?
What is the market cap of DURECT (DRRX)?
